Allergan and Richter Announce Phase 3 Study Of cariprazine Met Primary Endpoint In Study For1.5 mg and 3 mg Dose Groups vs Placebo; Co. Plans To Submit Supplemental New Drug Application To FDA In 2nd Half of 2018